Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 8/20 | 0.45 |
| ▸ | F13A1 | P00488 | 6/20 | 0.45 |
| ▸ | TGM1 | P22735 | 6/20 | 0.45 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821324 | 0.90 | MEN1 (0.48) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL2823484 | 0.85 | MAPT (0.53) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL13380238 | 0.84 | MEN1 (0.45) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL2819224 | 0.84 | KMT2A (0.47) | MEN1KMT2ACYP3A4CYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL2825072 | 0.83 | KMT2A (0.47) | MEN1KMT2ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL2823351 | 0.80 | MAPT (0.54) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL2823024 | 0.79 | F13A1 (0.43) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL2821444 | 0.79 | F13A1 (0.46) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL2819491 | 0.78 | TGM2 (0.45) | MEN1KMT2ATGM2F13A1TGM1 | |
| SCHEMBL2819856 | 0.77 | F13A1 (0.47) | MEN1KMT2ATGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1849469-B1 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1461038-B9 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1461038-B9 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1849469-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | Actimis Pharmaceuticals, Inc., (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1461038-B1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1461038-B1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050070582-A1 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | BAYER HEALTHCARE AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | MEN1 4873/4885KMT2A 2753/4885TGM2 4277/4885 |
| US-20050070582-A1 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | CCR3, CCR1, CCR2 | MEN1 4873/4885KMT2A 2753/4885TGM2 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.